1<!DOCTYPE html>
2
3Anonymous
4/bestp
5/bestp/domrep.nsf
636E519E09B76FB1D8525831B006668C1
8
9
10
11
12
13
140
15
16
17/bestp/domrep.nsf/products/outcomes-based-contract-initiatives-disrupting-the-high-cost-of-prescription-medications?opendocument
18
19opendocument
20100.25.43.188
21
22
23www.best-in-class.com
24/bestp/domrep.nsf
25DB




Products & Services Managed Care Payer Market Research

Outcomes-Based Contract Initiatives: Disrupting the High Cost of Prescription Medications

ID: 5529


Features:

13 Info Graphics

6 Data Graphics

70+ Metrics


Pages/Slides: 25


Published: 2018


Delivery Format: Online PDF Document


 

License Options:
close

Single User: Authorizes use by the person who places the order or for whom the order was placed.

Sitewide: Authorizes use of the report for a geographic site. All people at site can view the report for a year and copies can be printed.

Corporate: Authorizes use for the entire company for a year and copies can be printed. No limitations for usage inside the company.




Buy Now

 


  • STUDY OVERVIEW
  • BENCHMARK CLASS
  • SPECIAL OFFER
Non-members: Click here to review a complimentary excerpt from "Outcomes-Based Contract Initiatives: Disrupting the High Cost of Prescription Medications"

STUDY OVERVIEW


In recent years there has been a rise in innovative arrangements and contracts between pharma companies and payer groups, prompting them to move away from traditional reimbursement models to a newer outcome-based models. Outcome-based contract (OBC) initiatives, a type of risk-sharing arrangement, link the cost of a drug to a measure of clinical efficacy or the total cost of care of the drug in practice.

But the complexities and risks inherent in these arrangements present many challenges for the
pharmaceutical industry.

Best Practices, LLC conducted this research project to provide a current picture of where the pharma industry is with outcomes-based contract initiatives; how well the agreements have met goals; what are timelines for creating agreements and the challenges companies have faced in developing agreements.

KEY TOPICS

  • Key Insights and Research Findings
  • Paving New Ways to Risk Sharing
  • Case Study: Harvard Pilgrim
  • Future Direction of OBCs

KEY METRICS

  • Where is your company's value/outcomes-based contract initiative on an overall maturity curve?
  • How effective have your value/outcomes-based agreements/activities been in achieving these goals?
  • For the value/outcomes-based agreements/activities you don't have in place, when does your company plan to implement them?
  • How important are each of these goals when implementing value/outcomes-based contracts?
  • To what degree was your company challenged when developing value/outcomes-based contract initiatives?

SAMPLE KEY FINDING

  • Challenges Arise From Current OBC Models: Pharmaceutical companies and payers frequently have difficulties agreeing on proper metrics used to evaluate drug effectiveness and patient outcomes. Metric identification varies throughout therapeutic areas; cancer survival is straightforward whereas chronic conditions do not produce clear outcomes.

METHODOLOGY

This study presents primary research conducted with 11 biopharmaceutical companies and a case study review of recent Harvard Pilgrim initiatives.


Industries Profiled:
Pharmaceutical; Biopharmaceutical; Biotech; Health Care; Consumer Products


Companies Profiled:
Novartis; Bioverativ; Neos Therapeutics; Organogenisis; Janssen; UCB Pharma; AstraZeneca; GlaxoSmithKline ; Pfizer; LEO Pharma; Nestle

If you purchase Best Practice Database document(s), you will have 30 days from the date of purchase to apply some or all of the cost of the document(s) toward the cost of a Full Access Individual, Pharma, Group or University Membership. Write us at DatabaseTeam@bestpracticesllc.com or call David Guinn at 919-767-9179 if you have any questions.